Возможности терапии эрдостеином в снижении частоты обострений хронической обструктивной болезни легких

При обострении хронической обструктивной болезни легких (ХОБЛ) ухудшается статус здоровья, повышаются частота госпитализаций, вероятность прогрессирования заболевания и риск неблагоприятного исхода. Одной из основных целей терапии стабильной ХОБЛ на сегодняшний день является снижение частоты обострений заболевания, в связи с этим крайне актуальным для клинической практики является расширение терапевтических возможностей в отношении данного показателя. Патогенетически обоснованным методом лечения ХОБЛ, направленным в т. ч. на снижение частоты обострений, является применение муколитических препаратов с антиоксидантными и противовоспалительными свойствами.

Целью работы явилось описание дополнительных возможностей фармакотерапии с использованием мукоативного препарата эрдостеина в качестве поддерживающей терапии ХОБЛ, направленной на профилактику обострений основного заболевания.

Заключение. Продемонстрировано, что применение эрдостеина у пациентов со стабильной ХОБЛ, в первую очередь II стадии по критериям Глобальной инициативы диагностики лечения и профилактики ХОБЛ (Global Initiative for Chronic Obstructive Lung Disease – GOLD), способствует снижению частоты и продолжительности обострений заболевания.

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2022 Report. Available at: https://goldcopd.org/2022-gold-reports-2

2. Aisanov Z., Avdeev S., Arkhipov V. et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 183-187. https://doi.org/10.2147/copd.s153770.

3. Wilkinson T.M.A., Donaldson G.C., Hurst J.R. et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 169 (12): 1298-1303. https://doi.org/10.1164/rccm.200310-1443OC.

4. Vijayasaratha K., Stockley R.A. Reported and unreported exacerbations of COPD: analysis by diary cards. Chest. 2008; 133 (1): 34-41. https://doi.org/10.1378/chest.07-1692.

5. Aaron S.D., Donaldson G.C., Whitmore G.A. et al. Time course and pattern of COPD exacerbation onset. Thorax. 2012; 67 (3): 238-243. https://doi.org/10.1136/thoraxjnl-2011-200768.

6. Perera W.R., Hurst J.R., Wilkinson T.M.A. et al. Infl tory changes, recovery and recurrence at COPD exacerbation. Eur. Respir. J. 2007; 29 (3): 527-534. https://doi.org/10.1183/09031936.00092506.

7. Donaldson G.C., Law M., Kowlessar B. et al. Impact of prolonged exacerbation recovery in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2015; 192 (8): 943-950. https://doi.org/10.1164/rccm.201412-2269OC.

8. Авдеев С.Н., Трушенко Н.В., Гайнитдинова В.В. и др. Лечение обострений хронической обструктивной болезни легких. Терапевтический архив. 2018; 90 (12): 68-75. https://doi.org/10.26442/00403660.2018.12.000011.

9. Seemungal T.A., Donaldson G.C., Bhowmik A. et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161 (5): 1608-1613. https://doi.org/10.1164/ajrccm.161.5.9908022.

10. Zheng J.P., Wen F.Q., Bai C.X. et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir. Med. 2014; 2 (3): 187-194. https://doi.org/10.1016/S2213-2600(13)70286-8.

11. Zheng J.P., Kang J., Huang S.Q. et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet. 2008; 371 (9629): 2013-2018. https://doi.org/10.1016/S0140-6736(08)60869-7.

12. Cazzola M., Rogliani P., Calzetta L. et al. Impact of mucolytic agents on COPD exacerbations: a pair-wise and network meta-analysis. COPD. 2017; 14 (5): 552‒563. https://doi.org/10.1080/15412555.2017.1347918.

13. Papi A., Avdeev S., Calverley P.M.A. et al. Use of mucolytics in COPD: a Delphi consensus study. Respir. Med. 2020; 175: 106190. https://doi.org/10.1016/j.rmed.2020.106190.

14. Rogers D.F. Mucoactive agents for airway mucus hypersecretory diseases. Respir. Care. 2007; 52 (9): 1176-1197. Available at: http://rc.rcjournal.com/content/52/9/1176

15. Zuin R., Palamidese A., Negrin R. et al. High dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin. Drug Invest. 2005; 25 (6): 401-408. https://doi.org/10.2165/00044011-200525060-00005.

16. Moretti M. Pharmacology and clinical effi acy of erdosteine in chronic obstructive pulmonary disease. Expert Rev. Respir. Med. 2007; 1 (3): 307-316. https://doi.org/10.1586/17476348.1.3.307.

17. Hotzinger H. Erdosteine or placebo combined with co-trimoxazole in the treatment of hypersecretive infectious bronchitis: a double blind clinical trial. Med. Praxis. 1991; 12: 171-181.

18. Zanasi A., Menarini A. Erdosteine versus N-acetylcysteine in the treatment of exacerbation of chronic bronchopneumopathies. Med. Praxis. 1991; 12: 207-217.

19. Ghiringhelli G. Cross-over study of efficacy and tolerability of erdosteine in the treatment of chronic obstructive bronchial disease in stable hypersecretive phase: controlled double-blind study vs placebo. Arch. Med. Int. 1995; 47 (4): 113-120.

20. Moretti M. Erdosteine: its relevance in COPD treatment. Expert Opin. Drug Metab. Toxicol. 2009; 5 (3): 333-343. https://doi.org/10.1517/17425250902814790.

21. Dal Negro R.W., Visconti M., Micheletto C., Tognella S. Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD. Pulm. Pharmacol. Ther. 2008; 21 (2): 304-308. https://doi.org/10.1016/j.pupt.2007.07.004.

22. Braga P. Bacterial adhesion to human cells. In: Edi-Aipo Scientifica. Pisa; 2000: 1-63.

23. Ricevuti G., Nazzone A., Uccelli E. et al. Influence of erdosteine, a mucolytic agent, on amoxicillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis. Thorax. 1988; 43 (8): 585-590. https://doi.org/10.1136/thx.43.8.585.

24. Moretti M., Bottrighi P., Dallari R. et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE study. Drugs Exp. Clin. Res. 2004; 30 (4): 143-152.

25. Cazzola M., Floriani I., Page C.P. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data. Pulm. Pharmacol. Ther. 2010; 23 (2): 135-144. https://doi.org/10.1016/j.pupt.2009.10.002.

26. Decramer M., Rutten-van Mölken M., Dekhuijzen P.N.R. et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005; 365 (9470): 1552-1560. https://doi.org/10.1016/S0140-6736(05)66456-2.

27. Jenkins C.R., Postma D.S., Anzueto A.R. et al. Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease. BMC Pulm. Med. 2015; 15: 97. https://doi.org/10.1186/s12890-015-0077-0.

28. Braga P.C., Dal Sasso M., Sala M., Gianelle V. Effects of erdosteine and its metabolites on bacterial adhesiveness. Arzneimittelforschung. 1999; 49 (4): 344-350. https://doi.org/10.1055/s-0031-1300425.

29. Dal Negro R.W., Wedzicha J.A., Iversen M. et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur. Respir. J. 2017; 50 (4): 1700711. https://doi.org/10.1183/13993003.00711-2017.

30. Calverley P.M., Page C., Dal Negro R.W. et al. Effect of erdosteine on COPD exacerbations in COPD patients with moderate airflow limitation. Int. J. Chron. Obstruct. Pulmon. Dis. 2019; 14: 2733-2744. https://doi.org/10.2147/COPD.S221852.

31. Jenkins C.R., Jones P.W., Calverley P.M. et al. Effi acy of salmeterol/ fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir. Res. 2009; 10 (1): 59. https://doi.org/10.1186/1465-9921-10-59.

32. Cazzola M., Page C., Roglisni P. et al. Multifaceted beneficial effects of erdosteine: more than a mucolytic agent. Drugs. 2020; 80 (17): 1799-1809. https://doi.org/10.1007/s40265-020-01412-x.

33. Rogliani P.R., Matera M.G., Page C. et al. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine and N-acetylcysteine. Respir. Res. 2019; 20 (1): 104. https://doi.org/10.1186/s12931-019-1078-y.

34. Wedzicha J.A., Banerji D., Chapman K.R. et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N. Engl. J. Med. 2016; 374 (23): 2222-2234. https://doi.org/10.1056/nejmoa1516385.

35. Martinez F.J., Vestbo J., Anderson J. et al. Eff of fl icasone furoate and vilanterol on exacerbations of COPD in patients with moderate airflow obstruction. Am. J. Respir. Crit. Care Med. 2017; 195 (7): 881-888. https://doi.org/10.1164/rccm.201607-1421OC.